Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia

被引:21
|
作者
Ben Ayed-Guerfali, Dorra [1 ]
Ben Kridis-Rejab, Wala [2 ]
Ammous-Boukhris, Nihel [1 ]
Ayadi, Wajdi [1 ]
Charfi, Slim [3 ]
Khanfir, Afef [2 ]
Sellami-Boudawara, Tahia [3 ]
Frikha, Mounir [2 ]
Daoud, Jamel [4 ]
Mokdad-Gargouri, Raja [1 ]
机构
[1] Univ Sfax, Ctr Biotechnol Sfax, Sidi Mansour St Km 6,BP 1177, Sfax 3038, Tunisia
[2] Habib Bourguiba Hosp, Dept Oncol, Sfax, Tunisia
[3] Habib Bourguiba Hosp, Dept Anatomopathol, Sfax, Tunisia
[4] Habib Bourguiba Hosp, Dept Radiotherapy, Sfax, Tunisia
关键词
Breast cancer; Ovarian cancer; BRCA1; BRCA2; Germline mutation; Genetic testing; NEGATIVE BREAST-CANCER; STOP CODON K3326X; HEREDITARY BREAST; FOUNDER MUTATIONS; BRCA2; MUTATIONS; MIDDLE-EASTERN; FAMILY-HISTORY; PREVALENCE; IDENTIFICATION; WOMEN;
D O I
10.1186/s12967-021-02772-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The incidence of breast cancer (BC) and/or ovarian cancer (OC) is increasing in Tunisia especially in young women and mostly those with family history. However, the spectrum of BRCA mutations remains little explored in Tunisian patients in particular in the southern region. Methods We sequenced the entire coding regions of BRCA1and BRCA2 genes using next generation sequencing (NGS) in 134 selected patients with BC and/or OC. Results Among the 134 patients, 19 (14.17%) carried pathogenic mutations (10 are BRCA1 mutation carriers and 9 are BRCA2 mutation carriers) that are mainly frameshift index (76.9%). Interestingly, 5 out of the 13 variants (38.46%) were found at least twice in unrelated patients, as the c.1310-1313 delAAGA in BRCA2 and the c.5030_5033 delCTAA that has been identified in 4/98 BC patients and in 3/15 OC patients from unrelated families with strong history of cancer. Besides recurrent mutations, 6 variant (4 in BRCA1 and 2 in BRCA2) were not reported previously. Furthermore, 3 unrelated patients carried the VUS c.9976A > T, (K3326*) in BRCA2 exon 27. BRCA carriers correlated significantly with tumor site (p = 0.029) and TNBC cases (p = 0.008). In the groups of patients aged between 31 and 40, and 41-50 years, BRCA1 mutations occurred more frequently in patients with OC than those with BC, and conversely BRCA2 carriers are mostly affected with BC (p = 0.001, and p = 0.044 respectively). Conclusions The overall frequency of the BRCA germline mutations was 14.17% in patients with high risk of breast/ovarian cancer. We identified recurrent mutations as the c.1310_1313 delAAGA in BRCA2 gene and the c.5030_5033 delCTAA in BRCA1 gene that were found in 4% and 20% of familial BC and OC respectively. Our data will contribute in the implementation of genetic counseling and testing for families with high-risk of BC and/or OC.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    Wojcik, P.
    Jasiowka, M.
    Strycharz, E.
    Sobol, M.
    Hodorowicz-Zaniewska, D.
    Skotnicki, P.
    Byrski, T.
    Blecharz, P.
    Marczyk, E.
    Cedrych, I.
    Jakubowicz, J.
    Lubinski, J.
    Sopik, V.
    Narod, S.
    Pierzchalski, P.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2016, 14
  • [32] BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: Novel mutations and unclassified variants
    Tazzite, Amal
    Jouhadi, Hassan
    Nadifi, Sellama
    Aretini, Paolo
    Falaschi, Elisabetta
    Collavoli, Anita
    Benider, Abdellatif
    Caligo, Maria Adelaide
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 687 - 692
  • [33] Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: The public health perspective
    Narod, Steven A.
    SALUD PUBLICA DE MEXICO, 2009, 51 : S191 - S196
  • [34] Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon
    Jalkh, Nadine
    Nassar-Slaba, Jinane
    Chouery, Eliane
    Salem, Nabiha
    Uhrchammer, Nancy
    Golmard, Lisa
    Stoppa-Lyonnet, Domique
    Bignon, Yves-Jean
    Megarbane, Andre
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2012, 10
  • [35] BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia
    Jakimovska, Milena
    Kostovska, Ivana Maleva
    Popovska-Jankovic, Katerina
    Kubelka-Sabit, Katerina
    Karadjozov, Mitko
    Stojanovska, Liljana
    Arsovski, Andreja
    Smichkoska, Snezhana
    Lazarova, Emilija
    Dimitrovska, Maja Jakimovska
    Plaseska-Karanfilska, Dijana
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (03) : 745 - 753
  • [36] BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer
    Sakamoto, Ikuko
    Hirotsu, Yosuke
    Nakagomi, Hiroshi
    Ouchi, Hidetaka
    Ikegami, Atsushi
    Teramoto, Katsuhiro
    Amemiya, Kenji
    Mochizuki, Hitoshi
    Omata, Masao
    CANCER, 2016, 122 (01) : 84 - 90
  • [37] Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
    Edaily, Sarah
    Abdel-Razeq, Hikmat
    ONCOTARGETS AND THERAPY, 2022, 15 : 815 - 826
  • [38] Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel
    Laitman, Yael
    Simeonov, Monica
    Herskovitz, Liron
    Kushnir, Anya
    Shimon-Paluch, Shani
    Kaufman, Bella
    Zidan, Jamal
    Friedman, Eitan
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1153 - 1157
  • [39] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453
  • [40] BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients
    Zhang, Yinmei
    Wu, Heming
    Gan, Caiyan
    Rao, Hui
    Wang, Qiuming
    Guo, Xueming
    BMC MEDICAL GENOMICS, 2024, 17 (01)